MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526350 | Name: MHY908
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MHY908 is a novel inhibitor of melanogenesis, potently inhibiting mushroom tyrosinase activity in a dose-dependent manner.

Chemical Structure

MHY908
MHY908
CAS#1393371-39-5

Theoretical Analysis

MedKoo Cat#: 526350

Name: MHY908

CAS#: 1393371-39-5

Chemical Formula: C17H14ClNO3S

Exact Mass: 347.0383

Molecular Weight: 347.81

Elemental Analysis: C, 58.71; H, 4.06; Cl, 10.19; N, 4.03; O, 13.80; S, 9.22

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 weeks
25mg USD 850.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
MHY908
IUPAC/Chemical Name
2-[4-(5-Chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid
InChi Key
HJOJVKDSEPDKSE-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H14ClNO3S/c1-17(2,16(20)21)22-12-6-3-10(4-7-12)15-19-13-9-11(18)5-8-14(13)23-15/h3-9H,1-2H3,(H,20,21)
SMILES Code
CC(C)(OC1=CC=C(C2=NC3=CC(Cl)=CC=C3S2)C=C1)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
MHY908 is a potent dual agonist of PPARα and PPARγ.
In vitro activity:
This study investigates the action of 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908) specifically in the inhibition of melanogenesis, a mushroom tyrosinase activity assay was performed. This study confirmed the inhibitory effect of MHY908 at various melanin concentrations using α-MSH-induced melanoma cells. These results indicate that MHY908 potently inhibited mushroom tyrosinase activity (IC50 = 8.19 μM) in a dose-dependent manner. Reference: Arch Pharm Res. 2015 Apr;38(4):505-11. https://pubmed.ncbi.nlm.nih.gov/25502981/
In vivo activity:
This study evaluated the neuroprotective effects of MHY908 in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mouse model of PD. Pretreatment with MHY908 attenuated MPTP-induced dopaminergic neuronal loss and motor deficit. MPTP-induced glial activations were mitigated by MHY908 in the nigrostriatal pathway, and MHY908 effectively blocked 1-methyl-4-phenylpyridinium (MPP+)-induced cell death and ROS production in SH-SY5Y neuroblastoma cells. Reference: Brain Res. 2019 Feb 1;1704:47-58. https://pubmed.ncbi.nlm.nih.gov/30273550/
Solvent mg/mL mM comments
Solubility
DMF:PBS (pH 7.2) (1:8) 0.1 0.29
DMSO 10.0 28.75
Ethanol 1.0 2.88
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 347.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Park MH, Kim SJ, Jeong HO, Moon KM, Son S, Kim DH, Kim HR, Kim MJ, Yun HY, Chun P, Je NK, Yokozawa T, Moon HR, Chung HY. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2015 Apr;38(4):505-11. doi: 10.1007/s12272-014-0532-0. Epub 2014 Dec 14. PMID: 25502981. 2. Lee Y, Cho JH, Lee S, Lee W, Chang SC, Chung HY, Moon HR, Lee J. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson's disease model. Brain Res. 2019 Feb 1;1704:47-58. doi: 10.1016/j.brainres.2018.09.036. Epub 2018 Sep 28. PMID: 30273550. 3. Park MH, Kim DH, Kim MJ, Lee EK, An HJ, Jeong JW, Kim HR, Kim SJ, Yu BP, Moon HR, Chung HY. Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats. J Gerontol A Biol Sci Med Sci. 2016 Mar;71(3):300-9. doi: 10.1093/gerona/glv043. Epub 2015 Jul 28. PMID: 26219845.
In vitro protocol:
1. Park MH, Kim SJ, Jeong HO, Moon KM, Son S, Kim DH, Kim HR, Kim MJ, Yun HY, Chun P, Je NK, Yokozawa T, Moon HR, Chung HY. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2015 Apr;38(4):505-11. doi: 10.1007/s12272-014-0532-0. Epub 2014 Dec 14. PMID: 25502981.
In vivo protocol:
1. Lee Y, Cho JH, Lee S, Lee W, Chang SC, Chung HY, Moon HR, Lee J. Neuroprotective effects of MHY908, a PPAR α/γ dual agonist, in a MPTP-induced Parkinson's disease model. Brain Res. 2019 Feb 1;1704:47-58. doi: 10.1016/j.brainres.2018.09.036. Epub 2018 Sep 28. PMID: 30273550. 2. Park MH, Kim DH, Kim MJ, Lee EK, An HJ, Jeong JW, Kim HR, Kim SJ, Yu BP, Moon HR, Chung HY. Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats. J Gerontol A Biol Sci Med Sci. 2016 Mar;71(3):300-9. doi: 10.1093/gerona/glv043. Epub 2015 Jul 28. PMID: 26219845.
1: Kim YR, Lee EK, Kim DH, Kim KM, Lee B, An HJ, Park JW, Moon KM, Park MH, Chung KW, Park JY, Kim SJ, Yun HY, Son S, Chun P, Moon HR, Chung HY. PPARα activation by MHY908 attenuates age-related renal inflammation through modulation of the ROS/Akt/FoxO1 pathway. Exp Gerontol. 2017 Jun;92:87-95. doi: 10.1016/j.exger.2017.03.015. Epub 2017 Mar 18. PubMed PMID: 28323024. 2: Park MH, Kim DH, Kim MJ, Lee EK, An HJ, Jeong JW, Kim HR, Kim SJ, Yu BP, Moon HR, Chung HY. Effects of MHY908, a New Synthetic PPARα/γ Dual Agonist, on Inflammatory Responses and Insulin Resistance in Aged Rats. J Gerontol A Biol Sci Med Sci. 2016 Mar;71(3):300-9. doi: 10.1093/gerona/glv043. Epub 2015 Jul 28. PubMed PMID: 26219845. 3: Park MH, Kim SJ, Jeong HO, Moon KM, Son S, Kim DH, Kim HR, Kim MJ, Yun HY, Chun P, Je NK, Yokozawa T, Moon HR, Chung HY. Inhibition of melanogenesis by 2-[4-(5-chlorobenzo[d]thiazol-2-yl)phenoxy]-2-methylpropanoic acid (MHY908). Arch Pharm Res. 2015 Apr;38(4):505-11. doi: 10.1007/s12272-014-0532-0. Epub 2014 Dec 14. PubMed PMID: 25502981. 4: Park MH, Park JY, Lee HJ, Kim DH, Park D, Jeong HO, Park CH, Chun P, Moon HR, Chung HY. Potent anti-diabetic effects of MHY908, a newly synthesized PPAR α/γ dual agonist in db/db mice. PLoS One. 2013 Nov 14;8(11):e78815. doi: 10.1371/journal.pone.0078815. eCollection 2013. PubMed PMID: 24244369; PubMed Central PMCID: PMC3828319.

View History

MGS0028

MGS0028